VRTX
Vertex Pharmaceuticals IncorporatedHealthcare · $133.9B market cap
Verdict
Share price
$504.73
close of Oct 3, 2026
Fair value
$260.12
Sticker Price
Payback Price
$104.05
buy price
VRTX is Overpriced: at $504.73 it trades 94% above its fair value of $260.12. Its buy price (Payback Price) is $104.05, 79% below today's price. Business quality is strong: all 5 key numbers clear the 10% bar.
How we valued it
Free Cash Flow. Sales grew 11% a year over the last 3 years, below the 15% we look for in a fast grower, so we value it on its free cash flow instead of an earnings forecast.
Business quality
5 of 5 clear the 10% bar. What are the Big Five?
Follow VRTX
Get notified when it reaches its buy price of $104.05. Free.
Create a free accountSuperinvestors
2 of the investors we track hold VRTX. Who we track
Insider activity
Since Jun 15, 2026: no open-market purchases, 6 sales worth $4.6M and 7 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
McKechnie Duncan
EVP, Chief Commercial Officer · 2026-07-02
Sold
$800K
Tatsis Ourania
EVP, Chief Reg. & Quality Off. · 2026-07-02
Sold
$787K
Liu Joy
EVP and Chief Legal Officer · 2026-07-01
Sold
$416K
Bozic Carmen
EVP and CMO · 2026-06-26
Sold
$288K
Bozic Carmen
EVP and CMO · 2026-06-18
Sold
$471K
Show all 6 salesShow fewer
Bozic Carmen
EVP and CMO · 2026-06-15
Sold
$1.8M
Other filings
van Grunsven Jasper
EVP, CP and NPPO · 2026-09-08
Award
8,682 shares
Ambrose Kristen
SVP & Chief Accounting Officer · 2026-08-28
Award
5,000 shares
SACHS BRUCE I
director · 2026-08-27
G-Gift
6,000 shares
Sachdev Amit
EVP Chief Patient & Ext Af Off · 2026-07-21
Award
8,251 shares
Tatsis Ourania
EVP, Chief Reg. & Quality Off. · 2026-07-21
Award
8,251 shares
Show all 7 other filingsShow fewer
Garber Alan M
director · 2026-07-15
Award
31.56 shares
SACHS BRUCE I
director · 2026-07-15
Award
99.941 shares
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works